European regulatory use and impact of subgroup evaluation in marketing authorisation applications
SourceDrug Discovery Today, 22, 12, (2017), pp. 1760-1764
Article / Letter to editor
Display more detailsDisplay less details
Drug Discovery Today
SubjectRadboudumc 18: Healthcare improvement science RIHS: Radboud Institute for Health Sciences
Marketing authorisation application dossiers relating to medicinal products containing new active substances and evaluated by the European Medicines Agency (EMA) over the period 2012-2015 were examined. Major objections and other concerns relating to efficacy and safety of the day 80 assessment reports were reviewed. Overall, approved products have more subgroup concerns than nonapproved products, which seems to be a consistent pattern. Subgroup analyses are mainly assessed to have the insurance that subgroups of patients that might lack a positive benefit: risk ratio will not be wrongly included in the approved treatment indication.
This item appears in the following Collection(s)
- Academic publications 
- Electronic publications 
- Faculty of Medical Sciences 
- Open Access publications 
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.